title: [A mannitol solution as an oral contrast medium in pelvic MRT].
abstract: OBJECTIVE
  Improvement of pelvic MRI using peroral administration of an aqueous mannitol solution.
  
  
  METHODS
  We retrospectively evaluated magnetic resonance examinations of 72 patients with suspected or proven pelvic abnormalities: In 36 patients, no bowel marking was carried out. In further 36 patients, we performed a contrast enhancement of the bowel by oral application of 1000 ml of an aqueous mannitol solution.
  
  
  RESULTS
  8/36 (22%) patients suffered from diarrhoea, nausea or meteorism as a result of mannitol application. In group 2, an excellent bowel marking of the small intestine could be obtained in 36/36 (100%) patients. Contrast enhancement of the bowel significantly improved delineation between intestinal structures and pelvic organs or pathologic lesions, respectively. In summary, bowel marking was desirable in 25/36 (69%) of group 1 and helpful in 26/36 (72%) of group 2.
  
  
  CONCLUSIONS
  Aqueous mannitol solution is a safe bowel contrast agent and improves the diagnostic value of pelvic MRI, but in some cases delineation between marked bowel and cystic pelvic lesions may be uncertain.
authors.affiliation: Klinik und Poliklinik für Radiologie, Johannes-Gutenberg-Universität Mainz.
authors.forename: K
authors.initials: K
authors.lastname: Schunk
authors.forename: W
authors.initials: W
authors.lastname: Kersjes
authors.forename: S
authors.initials: S
authors.lastname: Schadmand-Fischer
authors.forename: P
authors.initials: P
authors.lastname: Grebe
authors.forename: H U
authors.initials: HU
authors.lastname: Kauczor
authors.forename: M
authors.initials: M
authors.lastname: Thelen
mesh_terms: D000284:Administration, Oral; D016477:Artifacts; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D005682:Gadolinium / Q000009:adverse effects; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000295:instrumentation / Q000379:methods* / Q000706:statistics & numerical data; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects; D010388:Pelvis / Q000473:pathology*; D004369:Pentetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives; D012189:Retrospective Studies; D012601:Scopolamine; D018709:Statistics, Nonparametric
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; D008353:Mannitol; D004369:Pentetic Acid; D005682:Gadolinium; D012601:Scopolamine; D019786:Gadolinium DTPA
vernacular_title: Eine Mannitollösung als orales Kontrastmittel in der pelvinen MRT.